Ulrik Nielsen
Founder at MERRIMACK PHARMACEUTICALS, INC.
Net worth: 546 017 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gary Crocker | M | 72 | 20 years | |
Errik B. Anderson | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | 7 years |
Timothy R. Surgenor | M | - | - | |
Piotr Bobrowicz | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Logan Snyder | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Eric David Andersen | M | 46 | 5 years | |
Ana Radeljevic | F | 44 | 2 years | |
Noah Gabriel Levy | M | 45 | 5 years | |
Martin Leach | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | 1 years |
Johannes Nielsen | M | - |
Tidal Therapeutics, Inc.
Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | - |
Tony Sun | M | 52 |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Douglas Cole | M | 63 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 9 years |
Jason Camm | M | 35 |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Jason Coloma | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Douglas A. Lauffenburger | M | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 8 years |
Alaa Halawa | M | 42 |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | 2 years |
Fabian Hansen | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Gerald Sewack | M | - |
Tidal Therapeutics, Inc.
Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | - |
Ali Behbahani | M | - |
Tidal Therapeutics, Inc.
Tidal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Tidal Therapeutics, Inc. is a preclinical biotech company based in Quincy, MA. Tidal Therapeutics, Inc. focuses on developing nanoparticles that deliver to reprogram immune cells inside the body, with applications in oncology and immune diseases. Ulrik B. Nielsen has been the CEO of the company since 2018. Tidal Therapeutics was acquired by Sanofi on April 09, 2021 for $470 million. | - |
Trier Bryant | F | 40 |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Alex Kolicich | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Richard Peters | M | 61 | 2 years | |
Jean Franchi | F | 57 | 2 years | |
William A. Sullivan | M | 52 | 10 years | |
Yasir Al-Wakeel | M | 42 | 2 years | |
John Dineen | M | 61 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 4 years |
Anthony Sinskey | M | 83 | 22 years | |
Robert J. Mulroy | M | 59 | 17 years | |
Michael Porter | M | 76 | 8 years | |
Vivian Lee | M | 57 | 4 years | |
Jeffrey A. Munsie | M | 47 | 8 years | |
Gavin MacBeath | M | 54 | 24 years | |
William McClements | M | 60 | 6 years | |
Walter M. Lovenberg | M | 89 | 12 years | |
James Quigley | M | 71 | 7 years | |
Daryl C. Drummond | M | - | - | |
George Demetri | M | 67 | 2 years | |
James van B. Dresser | M | 82 | 15 years | |
Gordon J. Fehr | M | 90 | 16 years | |
Sarah Nash | F | 70 | 8 years | |
John Mendelsohn | M | 87 | 5 years | |
Russ Ray | M | 77 | 7 years | |
Brian L. Hamilton | M | 76 | 2 years | |
Keith Marshall | M | 56 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 2 years |
Jim Murray | M | - | 14 years | |
Scott Lauder | M | - | 3 years | |
Bob Silverman | M | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | 2 years |
Hewmun Lau | F | - | 2 years | |
Alexey A. Lugovskoy | M | 51 | 6 years | |
Thomas Wickham | M | - | 7 years | |
Samuel Agresta | M | 51 | 1 years | |
Michael Alfieri | M | 59 | 3 years | |
Sergio Santillana | M | 61 | 2 years | |
John L. Green | M | 44 | - | |
Kathleen Gallagher | F | - | 13 years | |
John Hohneker | M | 64 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | - |
Peter N. Laivins | M | 66 | 6 years | |
Birgit M. Schoeberl | M | - | 2 years | |
Vincent Simmon | M | - | - | |
Peter C. Lewis | M | - | - | |
Steven Wheelwright | M | 80 | - | |
Gary E. Frashier | M | 86 | - | |
John Green | M | 43 | 1 years | |
Michael R. Slater | M | 77 | 9 years | |
Thomas E. Needham | M | 60 | 1 years | |
James Scibetta | M | 59 | 8 years | |
Dana Robie | F | - | 4 years | |
Edward J. Stewart | M | 53 | 16 years | |
Fazal R. Khan | M | 74 | - | |
Lisa A. Evrén | F | - | 3 years | |
William J. Slichenmyer | M | 66 | 2 years | |
Clet Niyikiza | M | 65 | - | |
Ellen K. Forest | F | 60 | - | |
Heather Schwoebel | F | - |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 74 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ulrik Nielsen
- Personal Network